Skip to main content

OLMESARTAN/AMLODIPINE SANDOZ (Sandoz Pty Ltd)

Product name
OLMESARTAN/AMLODIPINE SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
134 (255 working days)
Active ingredients
Amlodipine besilate, Olmesartan medoxomil
Registration type
New generic medicine
Indication

OLMESARTAN/AMLODIPINE SANDOZ is indicated for the treatment of hypertension. Treatment should not be initiated with this fixed-dose combination (see Section 4.2 Dose and method of administration).

Help us improve the Therapeutic Goods Administration site